Microvessel density and area in pituitary microadenomas.
Microvessel density (MVD) and area (MVA) were assessed in 53 clinically silent pituitary microadenomas and in surrounding normal pituitary tissue using CD34 immunostaining and digital image analysis system. Twenty-one microadenomas (40%) were avascular; in the others, both MVD and MVA were significantly lower than in the normal pituitary tissue. No significant differences in MVD and MVA were found between hormonally immunonegative and immunopositive tumors or between different hormonal subtypes of immunopositive microadenomas. In microadenomas and in normal pituitary tissue, MVD and MVA were not significantly influenced by age or sex. These results suggest that pituitary adenomas at early developmental stage are either avascular or significantly less vascular than normal pituitary tissue and that differences in vascularity of pituitary adenomas associated with the variables of sex, age, clinical presentation and immunohistochemical phenotype reported in the literature can evolve with tumor growth and possibly acquire statistical significance in large macroadenomas.
Jasek
Ewa
E
Department of Histology, Jagiellonian University Medical College, 31-034 Krakow, Poland. ejasek@cm-uj.krakow.pl
Furgal-Borzych
Alicja
A
Lis
Grzegorz J
GJ
Litwin
Jan A
JA
Rzepecka-Wozniak
Ewa
E
Trela
Franciszek
F
D000236:Adenoma / Q000098:blood supply* / Q000737:chemistry / Q000473:pathology; D000324:Adrenocorticotropic Hormone / Q000032:analysis; D018952:Antigens, CD34 / Q000032:analysis; D005260:Female; D005640:Follicle Stimulating Hormone / Q000032:analysis; D019382:Human Growth Hormone / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D007986:Luteinizing Hormone / Q000032:analysis; D008297:Male; D055806:Microvessels / Q000737:chemistry / Q000473:pathology*; D009389:Neovascularization, Pathologic / Q000473:pathology; D010911:Pituitary Neoplasms / Q000098:blood supply* / Q000737:chemistry / Q000473:pathology; D011388:Prolactin / Q000032:analysis
D018952:Antigens, CD34; D019382:Human Growth Hormone; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
Microsc Res Tech. 2003 Jan 1;60(1):98-106
12500266
Clin Cancer Res. 2007 Jan 1;13(1):161-9
17200351
Oncogene. 1999 Sep 20;18(38):5356-62
10498889
Endocr Pathol. 1995 Summer;6(2):115-124
12114647
Int J Exp Pathol. 2007 Aug;88(4):271-7
17696908
Hum Pathol. 2005 Oct;36(10):1090-5
16226108
Virchows Arch. 2001 Jun;438(6):595-602
11469692
J Histochem Cytochem. 2006 Apr;54(4):385-95
16234507
Eur J Endocrinol. 2006 May;154(5):753-8
16645024
Endocr Rev. 2003 Oct;24(5):600-32
14570746
Clin Neuropathol. 1990 Sep-Oct;9(5):251-3
2272145
Hum Reprod. 2003 May;18(5):1088-93
12721189
J Clin Endocrinol Metab. 2000 Mar;85(3):1159-62
10720055
Endocr Relat Cancer. 2006 Sep;13(3):931-44
16954441
Am J Pathol. 1972 Apr;67(1):109-26
5055626
J Clin Endocrinol Metab. 2004 Jun;89(6):2890-6
15181073
Br J Cancer. 2005 Jan 17;92(1):94-101
15558070
J Endocrinol. 2000 May;165(2):475-81
10810311
Histol Histopathol. 2008 May;23(5):601-7
18283645
Neuropathology. 2009 Feb;29(1):40-4
18673444
Oncol Res. 2000;12(4):203-8
11341470
Endocr Pathol. 2004 Summer;15(2):131-9
15299199
Fertil Steril. 2002 Sep;78(3):581-6
12215337
Microsc Res Tech. 2003 Feb 1;60(2):231-5
12539177
Mod Pathol. 1998 Apr;11(4):329-33
9578082
Histopathology. 2001 Sep;39(3):310-9
11532042
Endocr Pathol. 1997 Autumn;8(3):189-193
12114722
Endocr Pathol. 2006 Summer;17(2):175-81
17159250
Virchows Arch. 1996 Jul;428(4-5):217-21
8764929